{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014147","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.427832+00:00","generated_at":"2026-05-23T01:33:03.303297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025","bullets":["Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).","Cash $7.4M at Mar 31, 2025, up from $5.5M at Dec 31, 2024.","BARDA Project NextGen award terminated unexpectedly; GEO-CM04S1 COVID vaccine continues.","Healthy adult booster data for GEO-CM04S1 expected Q2 2025; GEO-MVA trial starts H2 2025.","Gedeptin advancing to Phase 2 for recurrent head/neck cancer with checkpoint inhibitor."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014147","json":"https://secwatch.observer/filing/0001437749-25-014147.json","markdown":"https://secwatch.observer/filing/0001437749-25-014147.md","text":"https://secwatch.observer/filing/0001437749-25-014147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/0001437749-25-014147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/govx20250430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:33:03.303297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}